OnCo

EWSR1-FLI1 fusion

Short target page →

The fused gene that defines Ewing sarcoma: an aberrant transcription factor that has resisted 30 years of drug design. This dossier gathers the 0 products (0 approved), 0 trials, 1 pathway and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.

Biology

EWSR1-FLI1 is a fusion oncoprotein; the EWSR1 domain drives phase separation and recruits BAF, while the FLI1 ETS domain binds GGAA repeats to activate (e.g. NR0B1, NKX2-2) and, at canonical ETS sites, repress (e.g. TGFBR2, IGFBP3) target genes.

Where it is found
  • Ewing sarcoma (~85%)
  • EWSR1 fusions with other partners define desmoplastic small round cell tumour (EWSR1-WT1), clear cell sarcoma (EWSR1-ATF1), myxoid liposarcoma (FUS/EWSR1-DDIT3)
Class: transcription · Gene: EWSR1::FLI1 · Facts checked 2026-09-08 · Target page

Elsewhere: identifiers and databases

Built from HGNC, Ensembl, UniProt and ChEMBL ids

How common it is, by cancer

Full matrix →
CancerPrevalenceSource
Ewing sarcoma
85%
doi.org

Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.

Products by modality and phase

Browse products →

No product in the corpus is aimed at this target yet.

No trial in the corpus names this target or one of its products.

Resistance routes that involve this target

Unaddressed routes →

The resistance atlas has no route that names this target.

Pathways where it is a node

Pathway-to-drug matrix →
  • Transcriptional machinery & addiction
    Node: Fusion TFs (EWSR1-FLI1) · 4 druggable nodes

    Cancer cells run a few genes (MYC, their lineage factors, their fusion oncogenes) at extreme volume from giant control regions called super-enhancers. The amplifiers, BRD4, CDK7, CDK9 and Mediator, are the same in every cell, but cancers are unusually dependent on them, and that dependence is druggable.

    Which nodes have drugs →

Companion diagnostics and assays

Assay registry →

No companion diagnostic in the registry measures this target.

Preclinical models

All models →

No model entry for this target yet; check the cancer entries on the models page.

No open questions recorded for this target yet. Suggest one.

Key papers and the live literature

Preprints →
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this target: (TITLE:"EWSR1-FLI1 fusion" OR ABSTRACT:"EWSR1-FLI1 fusion" OR TITLE:"EWSR1::FLI1" OR ABSTRACT:"EWSR1::FLI1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EWSR1-FLI1 fusion, not a curated reading list.

Export

The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ewsr1-fli1.json. Licence CC BY 4.0.